Is there a role for immunotherapy in Hodgkin’s disease?


Published: June 23, 2009
Abstract Views: 127
PDF: 544
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

To date, most patients with Hodgkin’s lymphoma (HL) can be cured with chemotherapy, radiotherapy or combined modality treatment. However, current treatment is associated with severe side effects and late toxicities such as infertility, cardiovascular damage and secondary malignancies. Moreover, a fraction of patients suffers from refractory disease and cannot be cured with current approaches including high dose chemotherapy and stem cell transplant.

Supporting Agencies


Böll, B., & Engert, A. (2009). Is there a role for immunotherapy in Hodgkin’s disease?. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.757

Downloads

Citations